A Randomized-Withdrawal, Placebo-Controlled, Study Evaluating the Efficacy, Safety, and Tolerability of Tapentadol Extended-Release (ER) in Subjects With Chronic, Painful Diabetic Peripheral Neuropathy (DPN).

Trial Profile

A Randomized-Withdrawal, Placebo-Controlled, Study Evaluating the Efficacy, Safety, and Tolerability of Tapentadol Extended-Release (ER) in Subjects With Chronic, Painful Diabetic Peripheral Neuropathy (DPN).

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs Tapentadol (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 12 Jun 2012 Patient Global Impression of Change and Brief Pain Inventory-Short Form outcomes presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
    • 17 May 2012 Results have been presented at the 31st Annual Scientific Meeting of the American Pain Society according to a Janssen media release. Results were also summarised in the media release.
    • 11 May 2012 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top